Cancer-focused biopharmaceutical company Exelixis (EXEL 2.05%) reported its fourth-quarter earnings results after the bell tonight, delivering lower revenue and a wider loss than in the year-ago period.
For the quarter, Exelixis reported net product revenue from the sale of Cometriq, its only FDA-approved product to treat metastatic medullary thyroid cancer, of $4.3 million. By comparison, Exelixis reported no product revenue during this quarter last year. However, license and contracting revenue fell to $0 in the fourth-quarter of 2013 compared to $7.8 million during the fourth-quarter of 2012 stemming from amortized collaboration revenue with Bristol-Myers Squibb (BMY 0.31%), which has now been fully recognized.
Net loss for the quarter widened 35%, to $70.7 million from $52.2 million in the year-ago quarter, or to $0.38 from $0.28 per share. The wider loss was due to higher research and development expenses, which totaled $49.6 million during the quarter compared to $32.5 million in the comparable period last year, and a 39% increase in selling, general, and administrative expenses to $13.6 million. The company's sales force in the U.S. and EU was expanded in accordance with Cometriq's approval.
Since cash burn is an important aspect of any non-profitable biopharma company, Exelixis ended the year with $415.9 million in cash compared to $634 million at the end of 2012. It did, however, secure an additional $75.6 million in net proceeds after issuing 10 million shares of common stock in January, which is not included in the year-end cash figures.
As its press release notes, the company anticipates reporting top-line data from four ongoing pivotal trials this year, including its late-stage metastatic renal cancer (kidney cancer) and advanced hepatocellular cancer (liver cancer) trials involving Cometriq.
Looking ahead, Exelixis chose not to provide full-year sales guidance for Cometriq in 2014, and does not anticipate recording any significant contract and licensing revenue. Including non-cash expenses, Exelixis estimates its full-year costs and expenses will total $250 million-$280 million, with cash and cash equivalents ending fiscal 2014 at greater than $200 million.